226 related articles for article (PubMed ID: 32584924)
1. Association Between Medication Use and Bullous Pemphigoid: A Systematic Review and Meta-analysis.
Liu SD; Chen WT; Chi CC
JAMA Dermatol; 2020 Aug; 156(8):891-900. PubMed ID: 32584924
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis.
Guo W; Rathi S; Marquez J; Smith H; Kuruvilla A; Tonnesen MG; Salvemini JN
Arch Dermatol Res; 2023 Oct; 315(8):2207-2213. PubMed ID: 36867222
[TBL] [Abstract][Full Text] [Related]
3. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials.
Silverii GA; Dicembrini I; Nreu B; Montereggi C; Mannucci E; Monami M
Endocrine; 2020 Sep; 69(3):504-507. PubMed ID: 32236820
[TBL] [Abstract][Full Text] [Related]
4. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
Kridin K; Bergman R
JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
[TBL] [Abstract][Full Text] [Related]
5. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
[TBL] [Abstract][Full Text] [Related]
8. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
Phan K; Charlton O; Smith SD
Australas J Dermatol; 2020 Feb; 61(1):e15-e21. PubMed ID: 31215644
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials.
Yang W; Cai X; Zhang S; Han X; Ji L
Diabetes Metab Res Rev; 2021 Mar; 37(3):e3391. PubMed ID: 32741073
[TBL] [Abstract][Full Text] [Related]
10. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
[TBL] [Abstract][Full Text] [Related]
11. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
Lee SG; Lee HJ; Yoon MS; Kim DH
JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
[TBL] [Abstract][Full Text] [Related]
12. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
13. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
[TBL] [Abstract][Full Text] [Related]
14. Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System.
Huang L; Liu Y; Li H; Huang W; Geng R; Tang Z; Jiang Y
Int J Med Sci; 2021; 18(9):1946-1952. PubMed ID: 33850463
[No Abstract] [Full Text] [Related]
15. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
[TBL] [Abstract][Full Text] [Related]
17. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study.
Varpuluoma O; Försti AK; Jokelainen J; Turpeinen M; Timonen M; Tasanen K; Huilaja L
J Am Acad Dermatol; 2018 Dec; 79(6):1034-1038.e5. PubMed ID: 29803903
[TBL] [Abstract][Full Text] [Related]
18. Association between dipeptidyl peptidase-4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5-year population-based cohort study using the Japanese National Database.
Kuwata H; Nishioka Y; Noda T; Kubo S; Myojin T; Higashino T; Takahashi Y; Ishii H; Imamura T
J Diabetes Investig; 2022 Mar; 13(3):460-467. PubMed ID: 34559464
[TBL] [Abstract][Full Text] [Related]
19. Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients.
Shalmon D; Bar-Ilan E; Peled A; Geller S; Bar J; Schwartz N; Sprecher E; Pavlovsky M
Acta Derm Venereol; 2024 Apr; 104():adv26663. PubMed ID: 38576104
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
